Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health.
Authors:Robert A Kloner|||Arthur L Burnett|||Martin Miner|||Michael J Blaha|||Peter Ganz|||Irwin Goldstein|||Noel N Kim|||Tobias Kohler|||Tom Lue|||Kevin T McVary|||John P Mulhall|||Sharon J Parish|||Hossein Sadeghi-Nejad|||Richard Sadovsky|||Ira D Sharlip|||Raymond C Rosen
Journal: The journal of sexual medicine
Publication Type: Journal Article
Date: 2024
DOI: 10.1093/jsxmed/qdad163
ID: 38148297
Affiliations:
Affiliations
Department of Cardiovascular Research Pasadena, Huntington Medical Research Institutes, CA 91105, United States.|||Department of Urology, Johns Hopkins University, Baltimore, MD, United States.|||Men's Health Center, Miriam Hospital, Providence, RI, United States.|||Cardiology and Epidemiology, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, United States.|||Department of Medicine (PG); Department of Urology (TL, IDS); Department of Psychiatry and Behavioral Sciences, (RCR), University of California, San Francisco, San Francisco, CA, United States.|||Department of Sexual Medicine, Institute for Sexual Medicine, Alvarado Hospital, San Diego, CA, United States.|||Department of Sexual Medicine, Institute for Sexual Medicine, Alvarado Hospital, San Diego, CA, United States.|||Mayo Clinic, Rochester, MN, United States.|||Department of Medicine (PG); Department of Urology (TL, IDS); Department of Psychiatry and Behavioral Sciences, (RCR), University of California, San Francisco, San Francisco, CA, United States.|||Center for Male Health, Stritch School of Medicine at Loyola University Medical Center, Maywood, IL, United States.|||Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.|||Weill Cornell Medicine, New York, NY, United States.|||Department of Urology NY, NYU Langone Grossman School of Medicine, NY, United States.|||Department of Family and Community Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, United States.|||Department of Medicine (PG); Department of Urology (TL, IDS); Department of Psychiatry and Behavioral Sciences, (RCR), University of California, San Francisco, San Francisco, CA, United States.|||Department of Medicine (PG); Department of Urology (TL, IDS); Department of Psychiatry and Behavioral Sciences, (RCR), University of California, San Francisco, San Francisco, CA, United States.
Abstract
In 1999, 1 year after the approval of the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), the first Princeton Consensus Conference was held to address the clinical management of men with ED who also had cardiovascular disease. These issues were readdressed in the second and third conferences. In the 13 years since the last Princeton Consensus Conference, the experience with PDE5 inhibitors is more robust, and recent new data have emerged regarding not only safety and drug-drug interactions, but also a potential cardioprotective effect of these drugs.
